ML-193

ML-193

ML-193 is a chemical compound that has been studied for its potential therapeutic effects, particularly in the field of oncology. It is classified as a small molecule inhibitor and has been the subject of research due to its ability to interfere with specific cellular pathways involved in cancer cell proliferation.

Chemical Structure and Properties

ML-193 is a synthetic compound with a complex molecular structure. It is characterized by its unique arrangement of atoms, which allows it to interact with specific proteins within the cell. The molecular formula of ML-193 is C21H18N4O2, and it has a molecular weight of 358.39 g/mol.

Mechanism of Action

ML-193 functions primarily as an inhibitor of the PI3K/AKT/mTOR pathway, a critical signaling pathway that regulates cell growth, survival, and metabolism. By inhibiting this pathway, ML-193 can induce apoptosis, or programmed cell death, in cancer cells, thereby reducing tumor growth.

Pharmacokinetics

The pharmacokinetic profile of ML-193 includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. Studies have shown that ML-193 is well-absorbed when administered orally and has a moderate half-life, allowing for sustained activity in the body. It is metabolized primarily in the liver and excreted through the kidneys.

Clinical Applications

ML-193 has been investigated in preclinical and early-phase clinical trials for its efficacy in treating various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Results from these studies have shown promising anti-tumor activity, particularly in cancers that exhibit overactivation of the PI3K/AKT/mTOR pathway.

Side Effects and Safety

As with many targeted therapies, ML-193 can cause side effects, which may include nausea, fatigue, and hematological abnormalities. Ongoing research aims to optimize dosing regimens to minimize adverse effects while maintaining therapeutic efficacy.

Research and Development

The development of ML-193 is part of a broader effort to create targeted cancer therapies that offer improved specificity and reduced toxicity compared to traditional chemotherapy. Researchers continue to explore its potential in combination with other treatments, such as immunotherapy and radiotherapy, to enhance its effectiveness.

Also see

• PI3K/AKT/mTOR pathway
• Targeted cancer therapy
• Small molecule inhibitors
• Oncology

ML-193
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG